A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
Journal
DrugDiscoveryToday
Type
journal article
Date Issued
2025
Author(s)
Abstract
Despite a recent increase in FDA new drug approvals, leading pharmaceutical companies continue to
face R&D productivity challenges. This highlights the need to better understand the context of their
R&D concepts and related R&D outputs. Consequently, we conducted a systematic assessment of the impact of R&D expenditures, R&D intensities, mergers & acquisitions (M&A) deals and licensing
agreements on new drug approvals of leading pharmaceutical companies between 2012 and 2021. Our analysis provides key insights into differentiating R&D factors: whereas R&D expenditures and the
number of M&A deals correlate with the number of new drug approvals, our analysis shows no correlation with R&D intensity or the number of licensing agreements.
face R&D productivity challenges. This highlights the need to better understand the context of their
R&D concepts and related R&D outputs. Consequently, we conducted a systematic assessment of the impact of R&D expenditures, R&D intensities, mergers & acquisitions (M&A) deals and licensing
agreements on new drug approvals of leading pharmaceutical companies between 2012 and 2021. Our analysis provides key insights into differentiating R&D factors: whereas R&D expenditures and the
number of M&A deals correlate with the number of new drug approvals, our analysis shows no correlation with R&D intensity or the number of licensing agreements.
Language
English
Refereed
Yes
Publisher
Elsevier
Volume
30
Number
3
File(s)![Thumbnail Image]()
open.access
Name
25 DDT a case study.pdf
Size
718.78 KB
Format
Adobe PDF
Checksum (MD5)
e846ed9b057873c181bb1641eb7a4d46